Reclaim™ Deep Brain Stimulation (DBS) Therapy for OCD* is a long-term treatment that requires your involvement — as well as that of your healthcare team — to be successful.

Following the implantation of the Reclaim™ DBS system, you’ll work closely with your healthcare team to make sure the treatment meets your specific needs.


The length of hospitalization for implantation of the DBS system varies. Most individuals recover quickly and experience little discomfort while healing. However, doctors advise against overexertion for several weeks after implantation.

Your clinician will decide when to turn on your neurostimulator. It’s usually turned on after healing is complete (about 4 weeks).

Checkups and Monitoring

You may not experience immediate symptom relief from the treatment. In fact, it may take a few to several months after the procedure to reach maximum effect. Visits to your clinic for initial programming after surgery and periodic adjustments are a routine part of Reclaim™ DBS Therapy.

During these check-ups, your doctor may evaluate your comfort and range of motion in the area of the neurostimulator and extension. You may also have X-rays to check placement of the neurostimulation system.

Adjusting Stimulation Levels

Your clinician will program your neurostimulator to best manage your symptoms while minimizing side effects. Follow-up appointments will be scheduled to achieve the best symptom control for you. It may require several visits to adjust the stimulation before the best settings are determined.


The patient manual covers your DBS system and treatment. You will receive a copy after your implant procedure.

Information on this site should not be used as a substitute for talking with your doctor. Always talk with your doctor about diagnosis and treatment information.


Humanitarian Device: Authorized by Federal (U.S.A.) law for use as an adjunct to medications and as an alternative to anterior capsulotomy for treatment of chronic, severe, treatment-resistant obsessive-compulsive disorder (OCD) in adult patients who have failed at least three selective serotonin reuptake inhibitors (SSRIs). The effectiveness of this device for this use has not been demonstrated.